Skip to main content
. 2021 May 10;13(9):2284. doi: 10.3390/cancers13092284

Figure 4.

Figure 4

Effect of the combination of PLX4032 and U18666 A in LM16 R cells. (A) Apoptosis detection by Annexin V-binding assay upon treatment with U18666 A as single agent or combined with for 48 h. Histograms represent the mean ± SEM of 3 independent experiments. * p < 0.05 by one-way ANOVA followed by Bonferroni correction. (B) Western blot analyses of cells exposed to the drugs alone or in combination for 48 h and harvested for protein extraction. Equal loading is shown by tubulin. (C) Caspase 3/7 activation evaluated after treatment with PLX4032, alone or in combination with U18666 A, by subtracting the control level. * p < 0.05 by one-way ANOVA followed by Bonferroni correction compared to single agents. The levels were significantly increased for all the treatments compared to untreated control (p < 0.05). (D) Caspase 3/7 activation evaluated after treatment with PLX4032, orlistat and U18666 A, alone or in simultaneous combination for 72 h. * p < 0.05 by one-way ANOVA followed by Bonferroni correction compared to each single agent.